Navigation Links
KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K
Date:6/22/2009

ST. LOUIS, June 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) (the "Company") today announced that it received a letter from NYSE Regulation, Inc. (the "NYSE") on June 16, 2009 informing the Company that it is subject to certain procedures as specified in Section 802.01E of the NYSE's Listed Company Manual ("Section 802.01E") as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended March 31, 2009 (the "2009 Annual Report") with the Securities and Exchange Commission (the "SEC").

Section 802.01E provides that the NYSE will monitor the Company and the status of the Company's filing of the 2009 Annual Report for a six-month period from the filing due date for the 2009 Annual Report. If the 2009 Annual Report is not filed with the SEC upon expiration of such six-month period, the NYSE will, in its sole discretion, determine whether to provide the Company with an additional six-month period in which to file the 2009 Annual Report. The letter also states that, regardless of the procedures specified in Section 802.01E and if circumstances warrant, the NYSE could commence delisting procedures at any time during any period that is available to complete the filing of the 2009 Annual Report.

As previously disclosed in its Notification of Late Filing on Form 12b-25 filed with the SEC on June 2, 2009, the Company has been unable to timely file the 2009 Annual Report due to an ongoing internal investigation being conducted by the Audit Committee (the "Audit Committee") of the Board of Directors of the Company. While the Audit Committee's investigation has been substantially completed, the Audit Committee has referred certain matters with a potential financial reporting impact resulting from its investigation to management for resolution. Until these matters can be resolved, the Company will not be in a position to file the 2009 Annual Report with the SEC. The
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Synthetech, Inc. (OTC,Bulletin Board: NZYM) today announced that ... become Synthetech,s President and Chief Executive Officer. Since,September ... and Chief,Operating Officer. Dr. Hahn will replace as ... continue as Synthetech,s Chairman of the Board.,Synthetech intends ...
... Industrial Control Repair, Inc.,(ICR), headquartered in Warren, Michigan, ... their superior delivery of MRO Asset Management and,industrial ... asset management solutions and selling refurbished,industrial equipment to ... honor at the annual Honda of America Manufacturing,MRO ...
... it will be several years before there,s widespread use ... new imaging device could one day help doctors detect ... and more accurately, researchers report. , If left undetected ... or acute glaucoma attack, which can result in permanent ...
... and Other Providers Would Likely Demand Similar,Treatment Next Year, ... (PCMA) released a new ad today warning policymakers,that other ... demand the "same prompt-pay deal" next year if Congress ... Medicare., "Paying one group of Medicare providers twice ...
... NEW YORK, June 9 Officials with the U.S.,Fund ... Inc.,announced the donation and delivery of 100,000 doses of ... to the,government of the former Soviet republic of Moldova, ... country., The vaccine is a combination vaccine against ...
... more sleepy, restless and stressed , , MONDAY, June 9 ... cell phones may be placing their health at risk ... Swedish study suggests. , The finding was presented Monday ... Baltimore. , "The message is that adolescents who use ...
Cached Medicine News:Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 3Health News:Industrial Control Repair Named Honda of America Manufacturing's '2007 Supplier of the Year' 2Health News:New Imaging Tool Can Spot Glaucoma Risk 2Health News:New Imaging Tool Can Spot Glaucoma Risk 3Health News:New PCMA Ad: Pharmacist 'Prompt Pay' Will Trigger 'Domino Effect' Among Other Medicare Providers 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 3Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 2Health News:Too Much Cell Phone Time Takes Toll on Teen Sleep 3
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Dermatitis - India Drug Forecast and Market ... PharmaPoint: Atopic Dermatitis - ... 2022 Summary,Although the past decade ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ... in body fat content and preserved lean body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CUPERTINO, Calif. , July 1 DURECT Corporation (Nasdaq: DRRX ... which it may sell up to $50 million of its registered ... is not obligated to utilize any of the $50 million facility. ... this facility. , , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ), an emerging ... medical products in China , said today,that Rita Zheng Liu ... will present at the Global Hunter,Securities 2010 China Conference to be held ... , , ...
Cached Medicine Technology:DURECT Corporation Secures $50 Million Committed Equity Financing Facility 2DURECT Corporation Secures $50 Million Committed Equity Financing Facility 3Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 2Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 3
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: